Calidi Biotherapeutics, Inc. (CLDI)

NYSEAMERICAN: CLDI · Real-Time Price · USD
0.3350
+0.0948 (39.47%)
At close: Jul 8, 2025, 4:00 PM
0.5661
+0.2311 (68.99%)
After-hours: Jul 8, 2025, 8:00 PM EDT
39.47%
Market Cap 11.25M
Revenue (ttm) n/a
Net Income (ttm) -21.58M
Shares Out 33.59M
EPS (ttm) -1.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 46,526,700
Open 0.2468
Previous Close 0.2402
Day's Range 0.2398 - 0.3400
52-Week Range 0.2027 - 3.8900
Beta 0.94
Analysts n/a
Price Target n/a
Earnings Date Aug 12, 2025

About CLDI

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States. Its product pipeline comprises CLD-101, which is in Phase 1b/2 clinical trial for the treatment of high-grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck squamous cell carcinoma, and soft tissue sarcoma, which is in pre-clini... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 28
Stock Exchange NYSEAMERICAN
Ticker Symbol CLDI
Full Company Profile

Financial Performance

Financial Statements

News

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one...

18 hours ago - GlobeNewsWire

Calidi Biotherapeutics Announces Shareholder Letter from CEO

SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targe...

11 days ago - GlobeNewsWire

Innovation In Indexing: Why Passive ETFs Matter

For many of us, ETFs have been synonymous with passive management. Since the early 1990s, ETFs have followed in the footsteps of the most well-known passive ETF — the S&P 500 ETF Trust (SPY).

6 weeks ago - ETF Trends

Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor vir...

2 months ago - GlobeNewsWire

Global X Offers Precise U.S. Equity Exposure with Launch of Domestic Focused Funds

NEW YORK, April 16, 2025 /PRNewswire/ -- Global X Management Company LLC ("Global X"), the New York-based provider of exchange-traded funds (ETFs), today announced expanded access to U.S. equities wit...

2 months ago - PRNewsWire

Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targ...

3 months ago - GlobeNewsWire

Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targ...

3 months ago - GlobeNewsWire

Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform

SAN DIEGO, March 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor vir...

4 months ago - GlobeNewsWire

Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FLORIDA / ACCESS Newswire / February 28, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and OS Therapies Inc. (NYSE American:OSTX) on the ...

Other symbols: OSTX
4 months ago - Accesswire

Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor viro...

4 months ago - GlobeNewsWire

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5

SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor viro...

5 months ago - GlobeNewsWire

Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement

SAN DIEGO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor viro...

5 months ago - GlobeNewsWire

Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor viro...

6 months ago - GlobeNewsWire

Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targe...

6 months ago - GlobeNewsWire

Calidi Biotherapeutics Announces Proposed Public Offering

SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targe...

6 months ago - GlobeNewsWire

Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock

SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor viro...

8 months ago - GlobeNewsWire

Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock

SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targe...

8 months ago - GlobeNewsWire

Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor viro...

8 months ago - GlobeNewsWire

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / October 25, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and Calidi Biotherapeutics, Inc. (NYSE American:CLDI) on the RedChip Smal...

Other symbols: NXL
9 months ago - Accesswire

Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences

- RTNova, an innovative systemic antitumor enveloped virotherapy, unlocks new possibilities in cancer therapy - RTNova addresses challenges posed by untargetable and untreatable metastatic diseases, o...

9 months ago - GlobeNewsWire

Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement

SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targe...

9 months ago - GlobeNewsWire

NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS)

SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor vir...

9 months ago - GlobeNewsWire

Calidi Biotherapeutics and Gorilla Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / October 18, 2024 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Gorilla Technology Group Inc. (Nasdaq:GRRR) on the RedChi...

Other symbols: GRRR
9 months ago - Accesswire

Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results

SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSEAM: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapi...

11 months ago - GlobeNewsWire

GreenPower Motor and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / August 2, 2024 / RedChip Companies will air interviews with GreenPower Motor Company Inc. (Nasdaq:GP) and Calidi Biotherapeutics, Inc. (NYSE American:CLDI) on the RedChip Sm...

Other symbols: GP
1 year ago - Accesswire